Nanobiotix (XPAR:NANO) Growth Rank : 0 (As of Jun. 06, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Nanobiotix Growth Rank?

Nanobiotix has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Nanobiotix Growth Rank Related Terms

Thank you for viewing the detailed overview of Nanobiotix's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanobiotix (XPAR:NANO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (XPAR:NANO) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

NBTX:USA 5NR:Germany

Address

60 Rue de Wattignies, Paris, FRA, 75012

Website

https://www.nanobiotix.com

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Nanobiotix (XPAR:NANO) Headlines

No Headlines